{"name":"AJU Pharm Co., Ltd.","slug":"aju-pharm-co-ltd","ticker":"","exchange":"","domain":"ajupharm.co.kr","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"A51R1 Tab. and A51R2 Tab.","genericName":"A51R1 Tab. and A51R2 Tab.","slug":"a51r1-tab-and-a51r2-tab","indication":"Other","status":"phase_1"},{"name":"AJU-C52H","genericName":"AJU-C52H","slug":"aju-c52h","indication":"Other","status":"phase_1"},{"name":"A51R2","genericName":"A51R2","slug":"a51r2","indication":"Other","status":"phase_3"},{"name":"AJU-A51 Tab.","genericName":"AJU-A51 Tab.","slug":"aju-a51-tab","indication":"Other","status":"phase_1"},{"name":"AJU-C52L","genericName":"AJU-C52L","slug":"aju-c52l","indication":"Other","status":"phase_1"},{"name":"AJU-C52L, AJU-C52","genericName":"AJU-C52L, AJU-C52","slug":"aju-c52l-aju-c52","indication":"Other","status":"phase_3"},{"name":"AJU-R713","genericName":"AJU-R713","slug":"aju-r713","indication":"Other","status":"phase_1"},{"name":"C52R1L, C52R1M","genericName":"C52R1L, C52R1M","slug":"c52r1l-c52r1m","indication":"Other","status":"phase_3"},{"name":"OM-89 [Uro-Vaxom® Capsule]","genericName":"OM-89 [Uro-Vaxom® Capsule]","slug":"om-89-uro-vaxom-capsule","indication":"Other","status":"marketed"},{"name":"Placebo Group(Vehicle)","genericName":"Placebo Group(Vehicle)","slug":"placebo-group-vehicle","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"AJU-A51","genericName":"AJU-A51","slug":"aju-a51","indication":"Type 2 diabetes","status":"phase_3"},{"name":"A51R3","genericName":"A51R3","slug":"a51r3","indication":"Type 2 diabetes","status":"phase_3"},{"name":"AJU-S56 5%","genericName":"AJU-S56 5%","slug":"aju-s56-5","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"B55R1 and B55R2","genericName":"B55R1 and B55R2","slug":"b55r1-and-b55r2","indication":"Type 2 diabetes","status":"marketed"},{"name":"B55R1 and placebo for B55R2","genericName":"B55R1 and placebo for B55R2","slug":"b55r1-and-placebo-for-b55r2","indication":"Atrial fibrillation for stroke prevention","status":"marketed"}]}],"pipeline":[{"name":"A51R1 Tab. and A51R2 Tab.","genericName":"A51R1 Tab. and A51R2 Tab.","slug":"a51r1-tab-and-a51r2-tab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AJU-A51","genericName":"AJU-A51","slug":"aju-a51","phase":"phase_3","mechanism":"AJU-A51 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AJU-C52H","genericName":"AJU-C52H","slug":"aju-c52h","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A51R2","genericName":"A51R2","slug":"a51r2","phase":"phase_3","mechanism":"A51R2 is an investigational drug with unknown mechanism of action.","indications":[],"catalyst":""},{"name":"A51R3","genericName":"A51R3","slug":"a51r3","phase":"phase_3","mechanism":"A51R3 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"AJU-A51 Tab.","genericName":"AJU-A51 Tab.","slug":"aju-a51-tab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AJU-C52L","genericName":"AJU-C52L","slug":"aju-c52l","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AJU-C52L, AJU-C52","genericName":"AJU-C52L, AJU-C52","slug":"aju-c52l-aju-c52","phase":"phase_3","mechanism":"AJU-C52L, AJU-C52 mechanism of action is not publicly available.","indications":[],"catalyst":""},{"name":"AJU-R713","genericName":"AJU-R713","slug":"aju-r713","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AJU-S56 5%","genericName":"AJU-S56 5%","slug":"aju-s56-5","phase":"phase_3","mechanism":"AJU-S56 5% is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"B55R1 and B55R2","genericName":"B55R1 and B55R2","slug":"b55r1-and-b55r2","phase":"marketed","mechanism":"B55R1 and B55R2 are inhibitors of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes","Heart failure"],"catalyst":""},{"name":"B55R1 and placebo for B55R2","genericName":"B55R1 and placebo for B55R2","slug":"b55r1-and-placebo-for-b55r2","phase":"marketed","mechanism":"B55R1 is a small molecule drug that works by inhibiting the activity of a specific enzyme.","indications":["Atrial fibrillation for stroke prevention","Hypertension"],"catalyst":""},{"name":"C52R1L, C52R1M","genericName":"C52R1L, C52R1M","slug":"c52r1l-c52r1m","phase":"phase_3","mechanism":"C52R1L and C52R1M are investigational drugs with unknown mechanisms of action.","indications":[],"catalyst":""},{"name":"OM-89 [Uro-Vaxom® Capsule]","genericName":"OM-89 [Uro-Vaxom® Capsule]","slug":"om-89-uro-vaxom-capsule","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo Group(Vehicle)","genericName":"Placebo Group(Vehicle)","slug":"placebo-group-vehicle","phase":"phase_3","mechanism":"A placebo (vehicle control) contains no active pharmaceutical ingredient and serves as an inert comparator in clinical trials.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5uSHJ4UjFNdHpmak5oT0ZKNmhKOEZLSlVIRlRTenoxYUkwelRDcEdYUWlyWEpHMjBZZFdTWnJrb21NSkJkVVY0b0g5TzhpajdhNkhZMGZhY9IBV0FVX3lxTE5uSHJ4UjFNdHpmak5oT0ZKNmhKOEZLSlVIRlRTenoxYUkwelRDcEdYUWlyWEpHMjBZZFdTWnJrb21NSkJkVVY0b0g5TzhpajdhNkhZMGZhYw?oc=5","date":"2026-04-03","type":"patent","source":"aju press","summary":"U.S. sets 15% tariff on Korean drugs, keeps biosimilars duty-free - aju press","headline":"U.S. sets 15% tariff on Korean drugs, keeps biosimilars duty-free","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE4xcTdsR0FvYV9kdG9BQThHOFFKUlFnbzdOajJxcTRWczRvVTUxYTNVOWUwUkU2cTNidXl0UnZTdTNuTUdVbUg1MGpMMkFDbGlmZzR0RExXc9IBV0FVX3lxTE4xcTdsR0FvYV9kdG9BQThHOFFKUlFnbzdOajJxcTRWczRvVTUxYTNVOWUwUkU2cTNidXl0UnZTdTNuTUdVbUg1MGpMMkFDbGlmZzR0RExXcw?oc=5","date":"2026-04-02","type":"pipeline","source":"aju press","summary":"Policy Split Deepens Divide Between Korea’s Pharma and Biotech Sectors - aju press","headline":"Policy Split Deepens Divide Between Korea’s Pharma and Biotech Sectors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1kamc3STMxanJzejl5X0I2d19zbzBpVEIyV1JIUG9Qemc3dzEtZTJudGlzX1hyYTRNc3ZPaGJkZk5leWdTLXlKSDRzSnFCNXRtTjVqVW13RdIBV0FVX3lxTE1kamc3STMxanJzejl5X0I2d19zbzBpVEIyV1JIUG9Qemc3dzEtZTJudGlzX1hyYTRNc3ZPaGJkZk5leWdTLXlKSDRzSnFCNXRtTjVqVW13RQ?oc=5","date":"2026-04-02","type":"pipeline","source":"aju press","summary":"Korean Pharma-Bio Briefing: Kolon Life Science, Daewoong, Celltrion, Daewon, Samsung Medical Center - aju press","headline":"Korean Pharma-Bio Briefing: Kolon Life Science, Daewoong, Celltrion, Daewon, Samsung Medical Center","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNbjlld0stX2d6WXAzaFBZeUdEVDlpMDVQTmFSZmM1ZlZORUdnbl9zOWxUUUh4UktsS3cyNE9fZWpHQm04T2g5SHM2Z18tNjNmUFpVOXV3bzdtbnRwX3JHTEIwRktFYkRleEZfVG9ZVEpzQ28xeWlJdHVqdndIYnQ0YmdpeGJMR0xHZWlleUdCWFpyelFZcTFLTHMwQQ?oc=5","date":"2025-08-26","type":"trial","source":"BioWorld News","summary":"Ribomic’s RBM-007 ready for phase III in achondroplasia - BioWorld News","headline":"Ribomic’s RBM-007 ready for phase III in achondroplasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE51SC1oaVVqMVg5bVhNNkJEOHVfa014RG1GbFFFZTBEUlMxZ2RnMzZGRTVFcDNZNUZRcWlOYXdMcVVfWHhDYk0zVmYxVVhBTzZzOGNYcE9CaExiYUNPZGpyOEdrelNnUk5JcXl2UzdR0gFyQVVfeXFMTUwxMUs0YW9UWS1ZQXdFemVkQVhRSDMxb3ZYb0RJWHJVdWo2SFBQZnp5RHZiMjBOTnpZcmRGOWtERE5EXzdBSjlDRGVHR2R6MjlySXRXMzV2VzZuZlJlUVhpd2ZDS2RNWnFzaEw2MEdHM2lR?oc=5","date":"2025-08-20","type":"pipeline","source":"koreabiomed.com","summary":"OliX secures ₩115 billion investment through convertible preferred shares - koreabiomed.com","headline":"OliX secures ₩115 billion investment through convertible preferred shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBmTXBxQjdXMC03a1Z3aG9QclhOc3lpMW9pbHBRR1Vwd2FISlNVVC1Jcmt6QlRVLTM1cmQtWkFIRlhxLWZGR0RKaFdHWXBWaHE4cW5CYW91SmNQTXpPekU2TTVHcE56MVZhSWxoVWdB0gFyQVVfeXFMTnVwYXFOTGtkb3BEN28xS19KaGNBbDVhc3JVWk1HdnlCNkRyYThOb1pjV3FDQW40VXFUelRjLU5ZaDlqa3BldEFYZE5fbzkydUFVMVB5UFF5aDR5MzJFUzIxZnBoNUx6UzNWaHJjTklhbVFR?oc=5","date":"2025-04-23","type":"trial","source":"koreabiomed.com","summary":"Aju Pharm successfully completes phase 3 trial of dry eye drug - koreabiomed.com","headline":"Aju Pharm successfully completes phase 3 trial of dry eye drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQeHhISHVyb2Z5d2h0aGoyZW4takJhLTlQaDlYbFFlaTRvMnBrN3h6cEttemhWelM0SzRkRFlzVlkzTkdET1dqb2xZcVdjZ0pKWGZIVnd0QnBDRHJjN0J3WXZmaWRpU0g4VndCYk9zSE94dF80VWNWX01MYXpJci02SFozdHlOdlR2TkM0ckNpdjBzVHE5U2hVUzc0U0dMODBXZkNYY08xOFh1OE53eWRRYi03cUIwQlh3d0JvTU41djhNMm9Mc3hBelZldmRETjlQd3ptNmlkY2RuQm9zR1F4WlMzeVQyUnhxeDdBSUNSbjRJX1NLVjI0ZEs0bmY3dWh4dDd1TFZKbjlpNTlIeXdqdm9PWG1mS3hEMTNTTmRjZw?oc=5","date":"2025-01-20","type":"trial","source":"globenewswire.com","summary":"Advancements in Ocular Hypertension Clinical Trial Pipeline - globenewswire.com","headline":"Advancements in Ocular Hypertension Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-07-19","type":"pipeline","source":"PR Newswire","summary":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer B","headline":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Ba","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQOFN1TGFBV3dZQjdaY2lfWGMtNkY0bFNlV2xxTVZiSHJxYnI3RlRXeWdxOUl6b1c0bDAxek9adkFFUFJIQ3hjaHFSMk9WUFB6OE1aWGQ5LXRDaUlYV1ZKSVI3RlBldTNVSmRpVFpLSEZJZ0lQUDlYQ1hPY05HUEtyVDBQSUlPNERybC1RM3JiNHFOeXFaWlgxaUFJRnRBWThFV25iaUdITm05eTIwREdGLVdGQnJtcTd3TThWXy1JdjlvRWFHeEo5Qk1hRQ?oc=5","date":"2023-01-03","type":"pipeline","source":"PR Newswire","summary":"Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd. - PR Newswire","headline":"Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE8xeXFWMnNlS1NNb2M1b3BoYlhWUkFEM2hJR1lDRktfcC1BUWJtRy1KQ2NXd3JLN2hHVGZhOEQyaUEwWEM4VWZMTXZXY0IzQ3h1VEVaMF96NA?oc=5","date":"2020-08-12","type":"trial","source":"바이오스펙테이터","summary":"Autotelic Bio expands its management team to accelerate clinical trial for ATB-301 and ASO based platform technology development - 바이오스펙테이터","headline":"Autotelic Bio expands its management team to accelerate clinical trial for ATB-301 and ASO based platform technology dev","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5VUHBoU1Y3MnIwSkpOVTRsNElxc3hSMEt3Vzk2VUJwMVJjVms3SWdKdTNlTjFDelhBT1FCVDNvZTFSLXNScm9NS19mN29ZeXlDOXRHMTV4Tm0yU24zOE43SXJFN1hzMzk4VzVPRtIBcEFVX3lxTE1sYkt0bjNXNHNQVmlGN3FsYll6NlN5X0pNejl5UEpKbDdHdF9Pb3ltLUhORExiLUJYZFFpWU1BX1hva0Vqb01GeHBCRTBuMHFUbzFyVmVRbHdEaEFJcjlfZFIyaXFra0VRdWpkcmFyQzg?oc=5","date":"2019-02-01","type":"patent","source":"koreabiomed.com","summary":"14 pharmaceuticals to release gastritis generic drugs soon - koreabiomed.com","headline":"14 pharmaceuticals to release gastritis generic drugs soon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1zREE4Z2dyaW9zNnFsUXZwR2hacnIwSWpFdV9mdmxkd0lKSlVTQWpvVzYzSjRFTjFPSktlSkFMeWtaaGwzVUVEc1JTYVRUcHY0a3hHeFkzam04MlFuekV6RDh1bHRSSWt6Zk1jZtIBcEFVX3lxTE16b0Y4VFRSZTVRbVFuUHBPQ3kxRHF5M0lzNU5JTUdIX0dUTU5MMTZJVVZDNTRyZDFnQlVOMWRNdU5tVGJJRGxhQ2NGZi02U2xMTjNObF9CbHp6XzNsTWUtSm50ZFBEaXFxaXBwVWd2RzE?oc=5","date":"2019-01-14","type":"patent","source":"koreabiomed.com","summary":"14 drugmakers to release generic copies of Stillen 2X in early February - koreabiomed.com","headline":"14 drugmakers to release generic copies of Stillen 2X in early February","sentiment":"neutral"}],"patents":[],"drugCount":15,"phaseCounts":{"phase_1":5,"phase_3":7,"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}